-
Capivasertib Extends Progression-Free Survival in Hormone Receptor-Positive Breast Cancer
The new AKT inhibitor doubled progression-free survival when added to treatment with Faslodex.
by Eric Fitzsimmons
-
Pregnancy After a Breast Cancer Diagnosis
Study finds pausing endocrine therapy is safe for early-stage breast cancer patients eager to expand their families.
by Thomas Celona
-
Disparities in Breast Cancer Outcomes for Black Women Despite Similar Recurrence Scores
Black breast cancer patients had worse outcomes in a recent study, even when cancer features aligned with white patients.
by Eric Fitzsimmons
Cancer Talk
Injection Immunotherapies Get FDA Approval
Giving immunotherapy drugs as injections, rather than intravenously, means patients can spend less time in the hospital or treatment center.
by Laura Gesualdi-Gilmore
Designing Clinical Trials for the PatientChallenges in developing and studying treatments call for new ways of thinking about cancer research.
by Eric Fitzsimmons
Treating Smoldering Multiple MyelomaA monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore